PHAR
Pharming Group·NASDAQ
--
--(--)
--
--(--)
3.24 / 10
Netural
The equity presents poor fundamental picture (3.2/10). Strengths include Days sales outstanding and Interest coverage ratio (EBIT / Interest expense) (%). This merits challenging consideration.
Analysis Checks(10/10)
Revenue-MV
Value-0.36
Score2/3
Weight14.74%
1M Return7.73%
Value-0.36
Score2/3
Weight14.74%
1M Return7.73%
Days sales outstanding
Value49.29
Score2/3
Weight1.64%
1M Return1.10%
Value49.29
Score2/3
Weight1.64%
1M Return1.10%
Net income-Revenue
Value-0.72
Score2/3
Weight15.03%
1M Return8.45%
Value-0.72
Score2/3
Weight15.03%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Asset-MV
Value-0.50
Score2/3
Weight19.36%
1M Return10.15%
Value-0.50
Score2/3
Weight19.36%
1M Return10.15%
Total operating revenue (YoY growth rate %)
Value31.82
Score2/3
Weight1.61%
1M Return1.11%
Value31.82
Score2/3
Weight1.61%
1M Return1.11%
Profit-MV
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
PB-ROE
Value1.05
Score2/3
Weight18.73%
1M Return9.14%
Value1.05
Score2/3
Weight18.73%
1M Return9.14%
Operating revenue (YoY growth rate %)
Value31.82
Score2/3
Weight0.62%
1M Return0.43%
Value31.82
Score2/3
Weight0.62%
1M Return0.43%
Cash-MV
Value-0.02
Score2/3
Weight14.76%
1M Return8.41%
Value-0.02
Score2/3
Weight14.76%
1M Return8.41%
Revenue-MV
Value-0.36
Score2/3
Weight14.74%
1M Return7.73%
Value-0.36
Score2/3
Weight14.74%
1M Return7.73%
Total operating revenue (YoY growth rate %)
Value31.82
Score2/3
Weight1.61%
1M Return1.11%
Value31.82
Score2/3
Weight1.61%
1M Return1.11%
Days sales outstanding
Value49.29
Score2/3
Weight1.64%
1M Return1.10%
Value49.29
Score2/3
Weight1.64%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
Net income-Revenue
Value-0.72
Score2/3
Weight15.03%
1M Return8.45%
Value-0.72
Score2/3
Weight15.03%
1M Return8.45%
PB-ROE
Value1.05
Score2/3
Weight18.73%
1M Return9.14%
Value1.05
Score2/3
Weight18.73%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value31.82
Score2/3
Weight0.62%
1M Return0.43%
Value31.82
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.36%
1M Return10.15%
Value-0.50
Score2/3
Weight19.36%
1M Return10.15%
Cash-MV
Value-0.02
Score2/3
Weight14.76%
1M Return8.41%
Value-0.02
Score2/3
Weight14.76%
1M Return8.41%
Is PHAR undervalued or overvalued?
- PHAR scores 3.24/10 on fundamentals and holds a Fair valuation at present. Backed by its -1.02% ROE, 0.02% net margin, 2885.87 P/E ratio, 4.17 P/B ratio, and 100.00% earnings growth, these metrics solidify its Netural investment rating.
